APOA5 and hypertriglyceridemia: Indeed, apoA5 has been documented as a target of several triglyceride-lowering drugs (Huang et al., 2009; Brautbar et al., 2011), and we previously demonstrated that apoA5 is implicated in the amelioration of hypertriglyceridemia in mice by metformin (Li et al., 2016), a drug for olanzapine-induced glucose and lipid disorder (Wu et al., 2008; Cernea et al., 2020).